Cardiol Therapeutics Inc Class A continues to show strong performance amid recent developments.
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) has seen a notable uptick in its stock price, reflecting growing investor interest and positive sentiment surrounding the company's ongoing clinical advancements. With a 1-week gain of 20.87% and a year-to-date increase of 83.09%, the stock's momentum is noteworthy as it approaches key milestones in its research and development efforts.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$289.33M
52W high
$2.69
52W low
$1.23
1W change
+20.87%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 141.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+141.0% Upside
Current Price
C$2.49
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.8%
Annualized
90-Day Vol
58.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.98
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.64 | C$2.08 – C$3.36 |
| 60 trading days | C$2.80 | C$1.99 – C$3.94 |
| 90 trading days | C$2.98 | C$1.96 – C$4.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should monitor Cardiol Therapeutics closely as it continues to advance its clinical trials, particularly in light of the recent publication highlighting its Phase II study results, which may enhance investor confidence and impact future stock performance.
Cardiol Therapeutics' Stock Surges 20.87% This Week
With a market cap of approximately C$289 million and a significant increase in trading volume, Cardiol Therapeutics is drawing attention from investors as it progresses through critical phases of drug testing.
Bull case
The recent publication of promising Phase II data in a reputable journal suggests strong potential for market acceptance of CardiolRx™. The company’s strategic financing efforts and ongoing clinical trials position it well for future growth.
Bear case
Despite recent gains, the company's negative return on equity and lack of profitability could pose risks. Investors should remain cautious as the company navigates the complex landscape of drug development.
Recent Price Action
Advertisement
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock price close at C$2.61, reflecting a 1-day decrease of 0.80%. However, the stock has performed exceptionally well over the past week, gaining 20.87%. Over the past month, it has surged by 47.34%, and year-to-date, it has risen by an impressive 83.09%. Such performance indicates strong investor interest, likely influenced by recent developments in the company's clinical trials.
Catalysts Behind the Movement
While there was no major company news this week, Cardiol Therapeutics recently gained attention due to the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. This study demonstrated that CardiolRx™ effectively reduced pericarditis pain and inflammation, which may have contributed to the recent stock price surge. Additionally, ongoing developments and strategic financial decisions have also played a role in boosting investor confidence.
Technical Picture
From a technical standpoint, Cardiol Therapeutics is currently trading well above its 50-day moving average of C$1.67 and its 200-day moving average of C$1.58, indicating strong upward momentum. The stock has a 52-week range of C$1.23 to C$2.69, with its current price sitting at approximately 95% of this range. The beta of 0.47 suggests that the stock is less volatile than the market, making it a potentially stable investment despite its recent fluctuations. The trading volume of 218,837 shares this week is significantly higher than the 20-day average of 165,284 shares, indicating heightened investor interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
